Evidence map›Paper›PMID 32418480›Full record

ReviewAntiviral chemistry & chemotherapy

Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular carcinoma: A literature review.

Mohamed A Abd El Aziz, Rodolfo Sacco, Antonio Facciorusso

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Antiviral chemistry & chemotherapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Recent Advances in Hepatitis B Treatment.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Mohamed A Abd El AzizDepartment of Surgery, Mayo Clinic, Rochester, MN, USA.
Rodolfo SaccoDepartment of Medical Sciences, Section of Gastroenterology, University of Foggia, Foggia Italy.
Antonio FacciorussoDepartment of Medical Sciences, Section of Gastroenterology, University of Foggia, Foggia Italy.ORCID https://orcid.org/0000-0002-2107-2156
University of Foggia · ITMayo Clinic in Arizona · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis B virus is mainly considered to cause hepatocellular carcinoma which is the fourth leading cause of cancer-related mortality worldwide. Treatment of Hepatitis B virus with nucleos(t)ide analogues can decrease the progression of the disease and subsequently decreases the incidence of hepatocellular carcinoma. In this review, we have discussed the different classes of nucleos(t)ide analogues used in the treatment of Hepatitis B virus and their relationship with the development of hepatocellular carcinoma. Furthermore, we discussed the effect of treatment of Hepatitis B virus with Nucleoside analogues (NAs) before, during and after surgery, chemoembolization, radiofrequency ablation, and chemotherapy for the treatment of hepatocellular carcinoma.

Indexed as

Antiviral AgentsCarcinoma, HepatocellularHepatitis B virusHumansLiver NeoplasmsMicrobial Sensitivity TestsNucleosidesNucleotidesAntiviral AgentsNucleosidesNucleotidesadefovirentecavirHepatitis B virusHepatocellular carcinomalamivudinenucleos(t)ide analoguestelbivudine interferontenofovir

Identifiers

PMID32418480
PMCPMC7232045
OpenAlexW3024433161

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.